Hikal Limited has informed the Exchange about Investor Presentation
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hikal Limited reported FY25 revenue of Rs 1,860 Cr, up 4% year-on-year, with EBITDA jumping 23% to Rs 328 Cr and margins expanding 270 basis points to 17.7%. Net profit grew 31% to Rs 91 Cr. Q4 FY25 was particularly strong, with revenue of Rs 552 Cr (up 7% YoY, 23% QoQ), EBITDA of Rs 123 Cr, and EBITDA margin of 22.4% (up 410 bps YoY). The pharmaceuticals business delivered 20% QoQ revenue growth to Rs 351 Cr, while crop protection revenue grew 30% QoQ to Rs 201 Cr, though global pricing pressure on active ingredients continues. The CDMO pipeline remains robust, the animal health business is transitioning from validation to commercialization with 8 products, and the Board has recommended a total dividend of Rs 1.40 per share (70% of face value) for FY25.
Strong margin expansion and debt reduction (Net Debt/Equity improved from 0.67 to 0.59) signal improving operational efficiency, likely to be viewed positively by investors. However, near-term margin pressure in the crop protection segment and macroeconomic headwinds from tariffs may temper near-term optimism despite the healthy FY25 performance and dividend payout.